ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 548

Persistence in Low Disease Activity or Remission with Etanercept Monotherapy in Patients with Rheumatoid Arthritis: Results from the Corrona Registry

Dimitrios A. Pappas1, Ying Shan2, Tamara Lesperance3, Sabrina Rebello2, Elaine Karis4, Greg Kricorian4, Winnie Hua5, Neil A. Accortt4 and Scott Stryker4, 1Corrona LLC, Waltham, MA, 2Corrona, LLC, Southborough, MA, 3DOCS Global, Inc., North Wales, PA, 4Amgen Inc., Thousand Oaks, CA, 5Corrona, LLC, Waltham, MA

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Disease Activity, Disease-modifying antirheumatic drugs, etanercept, remission and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, October 21, 2018

Session Title: Rheumatoid Arthritis – Treatments Poster I: Strategy and Epidemiology

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:  Monotherapy with etanercept (ETN) may be a viable therapeutic option for maintenance of patients with rheumatoid arthritis (RA) who prefer to eliminate potential burdens or side effects of combination therapy.  Our objective was to compare persistence of low disease activity (LDA)/remission in patients with RA who were on combination therapy with ETN and a conventional synthetic disease-modifying antirheumatic drug (csDMARD; most commonly methotrexate) who then either discontinued the csDMARD or continued on combination therapy.

Methods:  This analysis included RA patients from the Corrona registry during 10/1/2001–8/31/2017.  ETN monotherapy (Mono) patients were initially treated with ETN + csDMARD combination therapy, achieved Clinical Disease Activity Index (CDAI) LDA/remission (score ≤10), and discontinued the csDMARD (index visit).  The index visit for the comparator combination therapy (Combo) group (patients who continued on combination therapy) was selected as the date that had a similar time interval from the initiation visit as the Mono group.  Propensity score (PS) matching (1:2 without replacement) was used to ensure balanced groups and included variables selected a priori (baseline CDAI, RA duration, duration in LDA/remission before index) and variables not originally balanced between the Mono and Combo groups.  Cox regression was used to compare persistence in LDA/remission between the groups, overall and at specific time points, adjusted for any covariates that remained imbalanced after PS matching.  Patients were censored if disease activity increased to moderate or severe, ETN was discontinued, or a csDMARD was reinitiated (in patients in the Mono group).

Results: We identified 182 Mono and 403 Combo patients. After matching, 120 Mono and 207 Combo patients were eligible (45 on Mono had >3 years ETN before index date and could not be matched).  After PS matching, characteristics at index visit were similar between groups except prednisone dose (mean [standard deviation] 6.2 [2.6] for Mono, 4.7 [3.4] for Combo; standardized difference 0.488).  Models indicated that a substantial proportion of both Mono and Combo groups remained in LDA/remission through 24 months after the index date (Table).  The overall persistence in LDA/remission between Mono and Combo groups was not statistically different (P = 0.057).

Conclusion: Approximately 3 of 4 patients with RA remained on ETN Mono and maintained LDA/remission for 2 years after csDMARD discontinuation.  Although Combo persistence was numerically greater than Mono, the high level of persistence with ETN Mono following achievement of LDA/remission and discontinuation of csDMARD suggests that ETN Mono may be a viable option for patients who cannot adhere to or tolerate csDMARDs.

Persistence in LDA/Remission*

Time after index visit

ETN Mono
(N = 120)

ETN + csDMARD Combo
(N = 207)

6 months

0.88

0.96

12 months

0.77

0.92

18 months

0.75

0.89

24 months

0.75

0.86

*Models were adjusted for sex, race, age group, insurance type, anti-cyclic citrullinated peptide antibody status, and prior csDMARD use.

 


Disclosure: D. A. Pappas, Corrona, LLC, 3,Novartis, 9; Y. Shan, Corrona, LLC, 3; T. Lesperance, Amgen Inc., 5; S. Rebello, Corrona, LLC, 3; E. Karis, Amgen Inc., 1,Amgen Inc., 3; G. Kricorian, Amgen Inc., 1,Amgen Inc., 3; W. Hua, Corrona, LLC, 3; N. A. Accortt, Amgen Inc., 1,Amgen Inc., 3; S. Stryker, Amgen Inc., 1,Amgen Inc., 3.

To cite this abstract in AMA style:

Pappas DA, Shan Y, Lesperance T, Rebello S, Karis E, Kricorian G, Hua W, Accortt NA, Stryker S. Persistence in Low Disease Activity or Remission with Etanercept Monotherapy in Patients with Rheumatoid Arthritis: Results from the Corrona Registry [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 10). https://acrabstracts.org/abstract/persistence-in-low-disease-activity-or-remission-with-etanercept-monotherapy-in-patients-with-rheumatoid-arthritis-results-from-the-corrona-registry/. Accessed May 17, 2022.
  • Tweet
  • Email
  • Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/persistence-in-low-disease-activity-or-remission-with-etanercept-monotherapy-in-patients-with-rheumatoid-arthritis-results-from-the-corrona-registry/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.